Hagens Berman Reminds AbbVie (NYSE: ABBV) Investors of Ongoing Investigation of AbbVie's Humira Sales Practices
SAN FRANCISCO,/PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in AbbVie Inc. (NYSE: ABBV) of the Firm's ongoing investigation of AbbVie's Humira sales practices. If you purchased or otherwise acquired AbbVie securities between October 25, 2013 and September 18, 2018 and continue to hold shares contact Hagens Berman Sobol Shapiro LLP. For more information visit:
or contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing
On September 18, 2018, Bloomberg reported California's insurance regulator is suing AbbVie, alleging that the Company gave illegal kickbacks to health-care providers in order to keep patients on its blockbuster rheumatoid arthritis drug Humira.
The California Department of Insurance accuses Abbvie of engaging "in a far-reaching scheme including both classic kickbacks – cash, meals, drinks, gifts, trips, and patient referrals – and more sophisticated ones – free and valuable professional goods and services to physicians to induce and reward Humira prescriptions."
This news drove the price of AbbVie shares down $2.76 to close at $92.61 on September 18, 2018.
"We're focused on investors' losses and whether AbbVie's senior management and its directors knew of the facts supporting accusations by the California Department of Insurance," said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding ABBV should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email ABBV@hbsslaw.com.
About Hagens Berman
View original content to download multimedia:http://www.prnewswire.com/news-releases/hagens-berman-reminds-abbvie-nyse-abbv-investors-of-ongoing-investigation-of-abbvies-humira-sales-practices-300747787.html
SOURCE Hagens Berman Sobol Shapiro LLP
Company Codes: NYSE:ABBV